Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor

Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2003, Pages 1318-1329

  Baraldi, Pier Giovanni ^a   Nuñez, Maria del Carmen ^a   Morelli, Anna ^a   Falzoni, Simonetta ^a   Di Virgilio, Francesco ^a   Romagnoli, Romeo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 (4 CHLOROPHENYL)PIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 (4 FLUOROBENZYL)PIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 (4 FLUOROPHENYL)PIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 (4 IODOPHENYL)PIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 (4 NITROPHENYL)PIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 BENZYLPIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENETHYLPIPERAZINE; 1 [N,O BIS(ISOQUINOLINESULFONYL)TYROSYL] 4 (4 FLUOROPHENYL)PIPERAZINE; ADENOSINE TRIPHOSPHATE; BENZENE DERIVATIVE; CALCIUM ION; CHLORINE; HALOGEN; INTERLEUKIN 1BETA; IODINE; PIPERAZINE DERIVATIVE; PURINE P2X RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOM; CALCIUM TRANSPORT; CELL MEMBRANE TRANSPORT; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNITY; MACROPHAGE; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADENOSINE TRIPHOSPHATE; ARYLSULFONATES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM; CELLS, CULTURED; ETHIDIUM; HUMANS; INTERLEUKIN-1; MACROPHAGES; MONOCYTES; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 0242585424     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021049d     Document Type: Article

References (32)

1. Boarder, M. R.; Hourani, S. M. O. The regulation of vascular function by P2 receptors: multiple site and multiple receptors. Trends Pharmacol. Sci. 1998, 19, 99-107.
2. King, B. F.; Townsend-Nicholson, A.; Burnstock, G. Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. Trends Pharmacol. Sci. 1998, 19, 506-514.
3. Abbracchio, M. P. P1 and P2 receptors in cell growth and differentiation. Drug Dev. Res. 1996, 39, 393-406.
4. Di Virgilio, F.; Chiozzi, P.; Ferrari, D.; Falzoni, S.; Sanz, J. M.; Morelli, A.; Torboli, M.; Bolognesi, G.; Baricordi, O. R. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001, 97, 587-600.
5. Abbracchio, M. P.; Burnstock, G. Purinoreceptors: are there families of P2X and P2Y receptors? Pharmacol. Ther. 1994, 64, 445-475.
6. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharm. Rev. 1998, 50, 413-492.
7. Burnstock, G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol. Sci. 2001, 22, 182-188.
8. Di Virgilio, F. The P2Z purinoreceptor: an intriguing role in immunity, inflammation and cell death. Immunol. Today 1995, 16, 524-528.
9. Buell, G.; Collo, G.; Rassendren, F. P2X receptors: an emerging channel family. Eur. J. Neurosci. 1996, 8, 2221-2228.
10. North, R. A.; Surprenant, A. Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 563-580.
11. Khakh, B. S.; Burnstock, G.; Kennedy, C.; King, B. F.; North, A.; Séguéla, P.; Voight, M.; Humphrey, P. P. A. International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev. 2001, 53, 107-118.
12. Valera, S.; Hussy, N.; Evans, R. J.; Adami, N.; North, R. A.; Suprenant, A.; Buell, G. A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature 1994, 371, 516-519.
13. 7). Science 1996, 272, 735-738.
14. Steinberg, T. H.; Newman, A. S.; Swanson, J. A.; Silverstein, S. C. ATP4-permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J. Biol. Chem. 1987, 262, 8884-8888.
15. Falzoni, S.; Munerati, M.; Ferrari, D.; Spisani, S.; Moretti, S.; Di Virgilio, F. The purinergic P2Z receptor of human macrophage cells. J. Clin. Invest. 1995, 95, 1207-1216.
16. Rassendren, F.; Buell, G.; Virginio, C.; Collo, G.; North, R. A.; Suprenant, A. The permeabilizing ATP receptor P2 x 7: cloning of a human cDNA. J. Biol. Chem. 1997, 272, 5482-5486.
17. Collo, S.; Neidhart, S.; Kawashima, E.; Kosco-Vilbois, M.; North, R. A.; Buell, G. Tissue distribution of the P2X7 receptor. Neuropharmacology 1997, 36, 1277-1284.
18. 7 Receptor: A Pivotal Role in Inflammation and Immunomodulation. Drug Dev. Res. 1998, 45, 207-213.
19. Ferrari, D.; La Sala, A.; Chiozzi, P.; Morelli, A.; Falzoni, S.; Girolomoni, G.; Idzko, M.; Dichmann, S.; Norgauer, J.; Di Virgilio, F. The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J. 2000, 14, 2466-2476.
20. Perregaux, D.; Gabel, C. A.; Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 1994, 269, 15195-15203.
21. Ferrari, D.; Chiozzi, P.; Falzoni, S.; Hanau, S.; Di Virgilio, F. Purinergic modulation of interleukin-1β release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med. 1997, 185, 579-582.
22. Gargett, C. E.; Wiley, J. S. The isoquinoline derivative KN-62: a potent antagonist of the P2Z receptor of human lymphocytes. Br. J. Pharmacol. 1997, 120, 1483-1490.
23. 7 receptor. Br. J. Pharmacol. 1998, 124, 1314-1320.
24. 7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol. Pharmacol. 1998, 54, 22-32.
25. Baraldi, P. G.; Romagnoli, R.; Tabrizi, M. A.; Falzoni, S.; Di Virgilio, F. Synthesis of conformationally constrained analogues of KN-62, a potent antagonist of the P2X7-receptor. Bioorg. Med. Chem. Lett. 2000, 10, 681-684.
26. 7receptor containing the tyrosine moiety. Arzneim.-Forsch. 2002, 52, 273-285.
27. Ravi, R. G.; Kertesy, S. B.; Dubyak, G. R.; Jacobson, K. A. Potent P2X7 receptor antagonists: tyrosyl derivatives synthesized using a sequential parallel synthetic approach. Drug Dev. Res. 2001, 54, 75-87.
28. Boger, D. L.; Yohannes, D. Studies on the total synthesis of bouvardin and deoxybouvardin: cyclic hexapeptide cyclization studies and preparation of key partial structures. J. Org. Chem. 1988, 53, 487-499.
29. All arylpiperazines were commercially available with the exception of N-(4-cyanophenyl)piperazine prepared following the procedure reported in the following article. Kiritsy, J. A.; Yung, D. K.; Mahony, D. E. Synthesis and quantitative structure-activity relationships of some antibacterial 3-formylrifamycin SV N-(4-substituted phenyl)piperazinoacethydrazones. J. Med. Chem. 1978, 21, 1301-1307.
30. Morikawa, A.; Sone, T.; Asano, T. 5-Isoquinolinesulfonamide derivatives. 2. Synthesis and vasodilatatory activity of N-(2-guanidinoethyl)-5-isoquinolinesulfonamide derivatives. J. Med. Chem. 1989, 32, 42-46.
31. Morikawa, A.; Sone, T.; Asano, T. 5-Isoquinolinesulfonamide derivatives. 2. Synthesis and vasodilatatory activity of N-(2aminoethyl)-5-isoquinolinesulfonamide derivatives. J. Med. Chem. 1989, 32, 46-50.
32. Colotta, F.; Re, F.; Muzio, M.; Bertini, R.; Polentarutti, N.; Sironi, M.; Giri, J. G.; Dower, S. K.; Sims, J. E.; Mantovani, A. Interleukin-1 type II receptor: a decoy target for interleukin-1 regulated by interleukin-4. Science 1993, 261, 472-474.